Evidence map›Paper›PMID 39260412›Full record

ArticleApplied clinical informatics2024

Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer Centers.

Carlos Berenguer Albiñana, Matteo Pallocca, Hayley Fenton, Will Sopwith, Charlie Van Eden, Olof Akre, Annika Auranen, François Bocquet, Marina Borges, Emiliano Calvo and 21 more

Erratum issuedAbstract read
In one paragraph

Article in Applied clinical informatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Carlos Berenguer AlbiñanaIQVIA, London, United Kingdom.
Matteo PalloccaIRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy.
Hayley FentonIQVIA, London, United Kingdom.
Will SopwithIQVIA, London, United Kingdom.
Charlie Van EdenIQVIA, London, United Kingdom.
Olof AkreKarolinska Comprehensive Cancer Center, Stockholm, Sweden.
Annika AuranenTays Cancer Centre, Pirkanmaa, Finland.
François BocquetData Factory & Analytics Department, Institut de Cancérologie de l'Ouest, Nantes-Angers, France.
Marina BorgesIQVIA, London, United Kingdom.
Emiliano CalvoSTART Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.
John CorkettLeeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Serena Di CosimoFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Nicola GentiliIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.
Julien GuérinData Office, Institut Curie, Paris, France.
Sissel JorOslo University Hospital Cancer Center, Oslo, Norway.
Tomas KazdaMasaryk Memorial Cancer Institute, Brno, Jihomoravský, Czechia.
Alenka KolarInstitute of Oncology Ljubljana, Ljubljana, Slovenia.
Tim KuschelCharité, Universitätsmedizin Berlin, Berlin, Germany.
Maria Julia LostesVall d'Hebron University Hospital, Barcelona, Spain.
Chiara ParatoreUniversity Hospital San Luigi Gonzaga of Orbassano, Orbassano TO, Italy.
Paolo PedrazzoliFondazione I.R.C.C.S. Policlinico San Matteo, Pavia PV, Italy.
Marko PetrovicSestre Milosrdnice University Hospital, Zagreb, Croatia.
Jarno RaidTartu University Hospital, Tartu, Tartumaa, Estonia.
Miriam RocheTrinity St James's Cancer Institute, Dublin, Ireland.
Christoph SchatzBiobank Innsbruck, Innsbruck, Austria.
Joelle ThonnardCliniques Universitaires Saint-Luc, Brussels, Belgium.
Giovanni TononIRCCS San Raffaele Scientific Institute, Milan, Italy.
Alberto TraversoIRCCS San Raffaele Scientific Institute, Milan, Italy.
Andrea WolfUniversity Cancer Center Frankfurt (UCT), University Hospital, Goethe University, Frankfurt, Germany.
Ahmed H ZedanVejle Hospital, University of Southern Denmark, Vejle, Denmark.
Piers MahonIQVIA, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMulticenter precision oncology real-world evidence requires a substantial long-term investment by hospitals to prepare their data and align on common Clinical Research processes and medical definitions. Our team has developed a self-assessment framework to support hospitals and hospital networks to measure their digital maturity and better plan and coordinate those investments. From that framework, we developed PRISM for Cancer Outcomes: PR: agmatic I: nstitutional S: urvey and benchM: arking.

objectivesThe primary objective was to develop PRISM as a tool for self-assessment of digital maturity in oncology hospitals and research networks; a secondary objective was to create an initial benchmarking cohort of >25 hospitals using the tool as input for future development.

methodsPRISM is a 25-question semiquantitative self-assessment survey developed iteratively from expert knowledge in oncology real-world study delivery. It covers four digital maturity dimensions: (1) Precision oncology, (2) Clinical digital data, (3) Routine outcomes, and (4) Information governance and delivery. These reflect the four main data types and critical enablers for precision oncology research from routine electronic health records.

resultsDuring piloting with 26 hospitals from 19 European countries, PRISM was found to be easy to use and its semiquantitative questions to be understood in a wide diversity of hospitals. Results within the initial benchmarking cohort aligned well with internal perspectives. We found statistically significant differences in digital maturity, with Precision oncology being the most mature dimension, and Information governance and delivery the least mature.

conclusionPRISM is a light footprint benchmarking tool to support the planning of large-scale real-world research networks. It can be used to (i) help an individual hospital identify areas most in need of investment and improvement, (ii) help a network of hospitals identify sources of best practice and expertise, and (iii) help research networks plan research. With further testing, policymakers could use PRISM to better plan digital investments around the Cancer Mission and European Digital Health Space.

Indexed as

Cancer Care FacilitiesBenchmarkingBiomedical ResearchHumansMedical OncologyNeoplasmsSurveys and Questionnaires

Identifiers

PMID39260412
PMCPMC11398970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.